According to GEPIA, significant differential overexpression of AKT1 was seen in invasive breast carcinoma, cholangiocarcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, esophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, kidney chromophobe, acute myeloid leukemia, brain lower-grade glioma, ovarian serous cystadenocarcinoma, sarcoma, skin cutaneous melanoma, and thymoma (Figure 1b). Here, AKT1 is linked to lymphoid neoplasm.